The Chair of Lieff Cabraser’s Native American Tribal Practice Group, Eric B. Fastiff has practiced complex litigation for over 25 years, working on numerous cases involving the drug, food, technology, finance, and natural resource industries. His clients include Native American tribes and their health providers, municipal and county governments, businesses, individuals, and consumer groups.
In 2018, Eric and the firm filed cases against the country’s major opioid pharmaceutical manufacturers and distributors on behalf of tribes and tribal health organizations located in Northern California and Northwestern Washington, as well as Alaskan native villages and Alaskan tribal health organizations, seeking justice and restitution for extraordinary medical costs and community depredations resulting from the negligent, indiscriminate, and profit-driven marketing of opioid drugs into native communities. Lieff Cabraser also serves on the Tribal Leadership Committee in the National Prescription Opiate Litigation, where we have obtained over $1.5 billion in negotiated settlements so far for federally-recognized Tribes and Tribal health organizations to address the opioids crisis.
We also serve as Plaintiffs’ Lead Counsel in the McKinsey & Co. National Prescription Opiate MDL, where the plaintiffs alleged McKinsey provided negligent marketing advice to Purdue Pharma and other opioid manufacturers. In September of 2023, McKinsey agreed to pay $269.5 million, including $39.5 million designated for participating federally-recognized Native American Tribes.
Eric and the firm represented numerous tribes, Alaskan native villages, and tribal health organizations in litigation against JLI and Altria for the harm caused by their vaping products. The case resulted in over $63 million in settlements for tribal entities.
Eric previously chaired the firm’s Antitrust Practice Group, and served as co-lead counsel in the California Cipro litigation, representing California consumers and third party payors in a state court class action lawsuit charging Bayer, Barr Labs, and other generic prescription drug manufacturers with a conspiracy to restrain competition in the sale of Bayer’s blockbuster antibiotic drug Ciprofloxacin, sold as Cipro. The 17-year litigation ultimately resulted in settlements totaling $399 million, a result the trial court described as “extraordinary.” Eric and the LCHB team’s work on the Cipro case led to recognition by California Lawyer and the Daily Journal as 2016 California Lawyers of the Year and receipt of the American Antitrust Institute’s 2017 award for Outstanding Private Practice Antitrust Achievement.
Eric also represented The Charles Schwab Corporation in a suit against several major banks for manipulating the London Interbank Offered Rate (LIBOR). He also successfully led the prosecution of a two week arbitration on behalf of a client that alleged both intellectual property and breach of contract claims. Eric’s other notable successes include representing businesses that purchased TFT-LCD panels and products in litigation charging that the world’s leading TFT-LCD manufacturers conspired to fix prices. The litigation resulted in settlements totaling over $470 million.
Published Work/Appearances
•Speaker, “Opportunities in Plaintiff-Side Tribal Law: A Conversation with Lieff Cabraser,” Berkeley Law, February 2024
•General Editor, California Class Actions Practice and Procedures, 2003 - 2009
•Coordinating Editor and Co-Author, California section of the ABA State Class Action Survey, 2003 - 2008
•“US Generic Drug Litigation Update,” Journal of Generic Medicines 212, 2004
•The Proposed Hague Convention on the Recognition and Enforcement of Civil and Commercial Judgments: A Solution to Butch Reynolds’s Jurisdiction and Enforcement Problems,” 28 Cornell International Law Journal 469, 1995
Honors & Awards
•Selected for inclusion by peers in The Best Lawyers in America in the field of “Litigation - Antitrust,” 2013 - 2026
•“Lawdragon 500 Leading Litigators in America,” Lawdragon, 2025, 2026
•“Lawdragon 500 Leading Lawyers in America,” Lawdragon, 2019-2026
•“Lawdragon 500 Leading Plaintiff Financial Lawyers in America,” Lawdragon, 2019-2025
•“Lawdragon Finalist,” Lawdragon, 2009
•“Thought Leader - Competition: Plaintiff,” Lexology Index 2025
•“Super Lawyer for Northern California,” Super Lawyers, 2010-2025
•“Top 100 Super Lawyers of Northern California,” Super Lawyers, 2020-2023
•“Lawyer of the Year for Antitrust Litigation,” Northern California, Best Lawyers, 2021
•“Plaintiffs’ Law Trailblazer, National Law Journal, 2018
•“Outstanding Private Practice Antitrust Achievement,” American Antitrust Institute, 2017
•“California Lawyer Attorney of the Year (CLAY) Award,” California Lawyer, 2016
•“Top Plaintiff Lawyers,” Daily Journal, 2016-2017
•“Leader in the Field” for Antitrust - Plaintiffs (California); Antitrust - Plaintiffs (Nationwide), Chambers USA, 2017
•“California Litigation Star,” Benchmark Litigation, 2013 - 2015
•“Top 100 Lawyers in California,” Daily Journal, 2013
•Legal 500 recommended lawyer, LegalEase, 2013
•“Top Attorneys in Business Law,” Super Lawyers Corporate Counsel Edition, 2012
In the News
•September 8, 2025
Twenty-Seven Lieff Cabraser Partners Named to 2026 “Lawdragon 500 Leading Litigators in America” List
•August 21, 2025
36 Lieff Cabraser Lawyers Named to 2026 Best Lawyers Listings
•August 21, 2025
Five Lieff Cabraser Attorneys Recognized in Lexology Index: Competition 2025
•June 30, 2025
28 Lieff Cabraser Attorneys Selected as 2025 Northern California Super Lawyers and Rising Stars
•June 6, 2025
Twenty-Four Lieff Cabraser Attorneys Named to Lawdragon’s “500 Leading Plaintiff Financial Lawyers” List for 2025
